Serum lipids as markers of prostate cancer occurrence and prognosis?

2015 ◽  
Vol 10 (2) ◽  
pp. 145-165 ◽  
Author(s):  
Rhonda Arthur ◽  
Alejo Rodríguez-Vida ◽  
Giorgia Zadra ◽  
Henrik Møller ◽  
Mieke Van Hemelrijck
Keyword(s):  
Prostate Cancer ◽  
Serum Lipids ◽  
Cancer Occurrence

scholarly journals Could inequalities of prostate cancer occurrence be explained by environmental risk factors?

2017 ◽  
Vol 27 (suppl_3) ◽  
Author(s):  
M Ćwieląg-Drabek ◽  
E Marchwińska-Wyrwa ◽  
A Piekut ◽  
I Hajok ◽  
A Spychała
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Environmental Risk ◽  
Environmental Risk Factors ◽  
Cancer Occurrence

scholarly journals A systematic review and meta-analysis on incidence of prostate cancer in Iran

2019 ◽  
Vol 9 (2) ◽  
pp. 92-98 ◽  
Author(s):  
Asaad Moradi ◽  
Mohammad Zamani ◽  
Emadoddin Moudi
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Incidence Rate ◽  
Meta Analysis ◽  
Scientific Information ◽  
Epidemiological Studies ◽  
Health Concern ◽  
Cross Sectional ◽  
Cancer Occurrence ◽  
Iranian Populations

Background: Prostate cancer is a global health concern. In Iran, its epidemiology is not precisely recognized. We aimed to evaluate incidence of prostate cancer among Iranian populations. Methods: In this systematic review, we searched the databases PubMed, Web of Sciences, Scopus and Google Scholar for English studies and the databases Magiran, Scientific information Database, IranMedex and IranDoc for Persian studies, using related keywords. The cross sectional articles published from inception to 31 December 2018 were included. Meta-analysis was conducted on the collected data with STATA software using random effects model. Results: Out of 763 articles initially obtained, 9 articles were finally included after applying the predefined exclusion criteria. Analysis of 9 studies on the incidence of prostate cancer showed a crude rate of 7.1 per 100000 population (95% confidence interval [CI]: 5.6-8.6). Also, the pooled age-standardized incidence rate was 8.7 per 100000 (95% CI: 6.7-10.4). Studies performed in the period 2004-2012 had significantly a higher pooled estimate of the crude incidence rate (9.2 per 100000 [95% CI: 7.9-10.4]) compared with those conducted in the period 1996-2003 (4.5 per 100000 [95% CI: 2.8-6.2]). This trend was also observed based on the age-standardized incidence rate (11 per 100000 [95% CI: 9.4-12.5] versus 6.3 per 100000[95% CI: 4-8.5]).Conclusion: Despite low rate of prostate cancer occurrence in Iran, it is recommended that preventive measures be taken against this disease by health policymakers. Also, more epidemiological studies are needed to better find out the pattern of prostate cancer among Iranian populations.

scholarly journals Risk Factors Associated with Prostate Cancer

2021 ◽  
Vol 11 (2) ◽  
pp. 188-193
Author(s):  
Arslan Habib ◽  
Ghulam Jaffar ◽  
Malik ShahZaib Khalid ◽  
Zahid Hussain ◽  
Syeda Wafa Zainab ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Seminal Fluid ◽  
Prostate Cancer Risk ◽  
Epidemiological Studies ◽  
Prostate Cell ◽  
Cancer Risk Factors ◽  
Keywords Prostate Cancer ◽  
Cancer Occurrence ◽  
Emerging Issues

Globally prostate cancer is the second most familiar and fifth-most hostile neoplasm among male individuals. One of the emerging issues in men is prostate cancer. The Prostate is a ductal small walnut-shaped gland situated in men below the urinary bladder that produces the seminal fluid for sperms provision and transportation. The risk of emerging prostate cancer during the man’s lifetime is one out of seven. According to the epidemiological studies, different environmental and genetic factors are associated with the progression of abnormal prostate cell growth which ultimately causes the development of cancerous cells. The chances of prostate cancer occurrence are more in those patients with familial member’s history, and it can be more by two to three-folds associated with first-rank relatives to get prostate cancer. In the current review different risk factors which are associated with the development of prostate cancer, are discussed. Keywords: Prostate cancer, Risk factors, Male, BRCA1, BRAC2.

scholarly journals Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study

2008 ◽  
Vol 26 (11) ◽  
pp. 1824-1829 ◽  
Author(s):  
Matthew R. Smith ◽  
S. Bruce Malkowicz ◽  
Franklin Chu ◽  
John Forrest ◽  
Paul Sieber ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Placebo Group ◽  
Total Cholesterol ◽  
Interim Analysis ◽  
Serum Lipids ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Phase Iii ◽  
Fasting Serum

Purpose Androgen-deprivation therapy (ADT) is associated with greater risk of incident coronary heart disease and hospital admission for myocardial infarction; treatment-related increases in serum lipids may contribute to greater cardiovascular disease risk. We evaluated the effects of toremifene, a selective estrogen-receptor modulator, on fasting serum lipid levels in men receiving ADT for prostate cancer. Patients and Methods In an ongoing, multicenter, double-blind, placebo-controlled phase III fracture-prevention study, 1,389 men receiving ADT for prostate cancer were randomly assigned to receive toremifene (80 mg/d) or placebo. In this interim analysis of 188 patients, changes in fasting serum lipids from baseline to month 12 were compared between the placebo and toremifene groups. Results Changes in serum lipids differed significantly between the groups. Mean (± SE) total cholesterol decreased by 1.0% ± 1.7% from baseline to month 12 in the placebo group and decreased by 8.1% ± 1.4% in the toremifene group (P = .001 for between group comparison). Low-density lipoprotein (LDL) cholesterol increased by 0.8% ± 2.5% in the placebo group and decreased by 8.2% ± 2.5% in the toremifene group (P = .003). In contrast, high-density lipoprotein (HDL) cholesterol decreased by 4.9% ± 1.2% in the placebo group and increased by 0.5% ± 2.2% in the toremifene group (P = .018). Triglycerides increased by 6.9% ± 4.2% in the placebo group and decreased by 13.2% ± 3.6% in the toremifene group (P = .003). Conclusion Toremifene significantly decreased total cholesterol, LDL cholesterol, and triglycerides, and increased HDL cholesterol in men receiving ADT for prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document